osimertinib
astrazeneca
['tagrisso', 'lung', 'adaura', 'astrazeneca', 'aura ,(-laura)']
exciting news from #asco23 in the #lungcancer space. read below! the asco 2023 data reveals astrazeneca's tagrisso demonstrated groundbreaking survival rates in early-stage egfr-mutated lung cancer. in the adaura phase iii trial, 88% of patients were 
Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines